HOME >> MEDICINE >> NEWS
Glaucoma treatment time and costs increase as disease progresses

Delaying the progression of the eye disease glaucoma from advancing to later stages is associated with lower cost of care, according to a study in the January issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Glaucoma affects an estimated 2.2 million Americans older than age 40 years, half of whom remain undiagnosed, the authors provide as background information in the article. "The incidence of glaucoma is expected to rise with the growth of the elderly population. Glaucoma costs the U.S. health care system an estimated $2.5 billion annually: $1.9 billion in direct costs and $0.6 billion in indirect costs," the authors write. Glaucoma is an eye disease characterized by damage to the optic nerve and loss of vision, usually the result of high pressure in the eye.

Paul P. Lee, M.D., J.D., from Duke University Medical Center, Durham, N.C., and colleagues analyzed 151 records of patients with primary open-angle or normal-tension glaucoma, glaucoma suspect, or ocular hypertension to determine if use of physician and other services for low vision care and vision rehabilitation, and direct costs of care increased with progression of disease severity.

"Direct ophthalmology-related resource use, including ophthalmology visits, glaucoma surgeries, and medication use, increased as disease severity worsened," the researchers found. "Average direct cost of treatment ranged from $623 per patient per year for glaucoma suspects or patients with early-stage disease to $2,511 per patient per year for patients with end-stage disease. Medication costs composed the largest proportion of total direct cost for all stages of disease." The researchers add that glaucoma is "generally asymptomatic or nonspecific in its symptoms in its earlier phases, resulting in delayed diagnosis and relatively increased medical vigilance throughout the later stages of the disease."


'"/>

Contact: Tracey Koepke
919-660-1301
JAMA and Archives Journals
9-Jan-2006


Page: 1

Related medicine news :

1. Glaucoma patients appear to have increased eye pressure during sleep
2. Spot on treatment for acne
3. New treatment boosts muscle function in myasthenia gravis
4. New treatment effective in counteracting cocaine-induced symptoms
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Preventive treatments in elderly people needs rethinking
7. Osteoporosis screening and treatment may be cost-effective for selected older men
8. Quality of treatment guidelines
9. Green tea holds promise as new treatment for inflammatory skin diseases
10. Many heart attack patients still not getting emergency clot-busting treatment
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Glaucoma treatment time and costs increase disease progresses

(Date:8/20/2014)... 20, 2014 Hope For The Warriors® ... Celebration to be hosted in Washington, DC on Thursday, ... This signature event honors the courage of our wounded ... fallen. Proceeds from the Got Heart, Give Hope® Celebration ... dedicated to restoring a sense of self, restoring the ...
(Date:8/20/2014)... WA (PRWEB) August 20, 2014 “Have you ... an auto accident and personal injury lawyer serving the greater ... that incident? If so, then keep reading . , ... that individuals injured in an auto accident can use to ... Jones explains that a personal injury insurance claim will allow ...
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:8/20/2014)... Burlingame, CA (PRWEB) August 20, 2014 ... publishers to speech-enable their websites and create a new ... users to consume content by listening to a narration ... in multiple reader genders and languages. Users can ... work, check social networks, while consuming content. ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 Over ... the Global Bureau of Disease, low back pain is the ... the most common reasons for missed work. Americans spend at ... this pain. , Most cases of back pain are not ... mechanical (non-organic) origin. , For example, Pete, a busy accountant, ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2
(Date:8/19/2014)... British Columbia and MENLO PARK, Calif. ... (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol ... trial had been filed with the U.S. Food and Drug ... 50mg/m 2 has been opened at three clinical trial ... company also confirmed that gross proceeds of US$2.9 million have ...
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Israel , Aug. 19, 2014 Immune ... Stockholm : "IMNP"), a biotechnology company, today announced ... its common stock on the NASDAQ Capital Market has been ... NASDAQ OMX Group. IMMUNE,s common stock is expected to begin ... trading on August 21, 2014 under the symbol IMNP. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
Cached News: